New cancer drug enters first human trials for advanced solid tumors
NCT ID NCT06724016
Summary
This is the first human study of an experimental drug called HM16390 for people with advanced solid tumors that have spread or don't respond to standard treatments. Researchers will test HM16390 alone and combined with an existing immunotherapy drug (pembrolizumab) to find safe doses and see if it helps control cancer. The study will enroll 292 adults to determine how the body processes the drug and whether it shows early signs of effectiveness against various tumor types.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
ACTIVE_NOT_RECRUITINGSeoul, 05505, South Korea
-
Karmanos Cancer Institute
NOT_YET_RECRUITINGDetroit, Michigan, 48201, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.